140 related articles for article (PubMed ID: 12750721)
1. Comparison of fludarabine-containing salvage chemotherapy regimens for relapsed/refractory acute myelogenous leukemia.
Thomas MB; Koller C; Yang Y; Shen Y; O'Brien S; Kantarjian H; Davis J; Estey E
Leukemia; 2003 May; 17(5):990-3. PubMed ID: 12750721
[No Abstract] [Full Text] [Related]
2. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
Camera A; Rinaldi CR; Palmieri S; Cantore N; Mele G; Mettivier V; Miraglia E; Mastrullo L; Grimaldi F; Luciano L; Guerriero A; Rotoli B; Ferrara F
Ann Hematol; 2009 Feb; 88(2):151-8. PubMed ID: 18709502
[TBL] [Abstract][Full Text] [Related]
3. Fludarabine, cytarabine and topotecan (FLAT) as induction therapy for acute myeloid leukemia in the elderly: a preliminary report.
Leoni F; Ciolli S; Nozzoli C; Santini V; Fanci R; Rossi Ferrini P
Haematologica; 2001 Jan; 86(1):104. PubMed ID: 11146581
[No Abstract] [Full Text] [Related]
4. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
Hołowiecki J; Grosicki S; Kyrcz-Krzemien S; Skotnicki AB; Piatkowska-Jakubas B; Warzocha K; Seferynska I; Zdziarska B
Ann Hematol; 2008 May; 87(5):361-7. PubMed ID: 18074133
[TBL] [Abstract][Full Text] [Related]
5. Induction chemotherapy for acute myelogenous leukemia.
Kalaycio M
Curr Hematol Rep; 2005 Jan; 4(1):49-50. PubMed ID: 15610659
[No Abstract] [Full Text] [Related]
6. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.
Holowiecki J; Grosicki S; Giebel S; Robak T; Kyrcz-Krzemien S; Kuliczkowski K; Skotnicki AB; Hellmann A; Sulek K; Dmoszynska A; Kloczko J; Jedrzejczak WW; Zdziarska B; Warzocha K; Zawilska K; Komarnicki M; Kielbinski M; Piatkowska-Jakubas B; Wierzbowska A; Wach M; Haus O
J Clin Oncol; 2012 Jul; 30(20):2441-8. PubMed ID: 22508825
[TBL] [Abstract][Full Text] [Related]
7. A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia.
Giles FJ; Cortes JE; Kantarjian HM; O'Brien SM; Estey E; Beran M
Leuk Res; 2004 Apr; 28(4):353-7. PubMed ID: 15109534
[TBL] [Abstract][Full Text] [Related]
8. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
[TBL] [Abstract][Full Text] [Related]
9. Intensive post-remission therapy with Ara-C in adults with acute myeloid leukemia: initial results of a CALGB phase III trial. The Cancer and Leukemia Group B.
Mayer RJ; Davis RB; Schiffer CA; Berg DT; Sarno E; Frei E
Leukemia; 1992; 6 Suppl 2():66-7. PubMed ID: 1578945
[No Abstract] [Full Text] [Related]
10. Comparison of clinical remission and survival between CLAG and FLAG induction chemotherapy in patients with refractory or relapsed acute myeloid leukemia: a prospective cohort study.
Bao Y; Zhao J; Li ZZ
Clin Transl Oncol; 2018 Jul; 20(7):870-880. PubMed ID: 29181696
[TBL] [Abstract][Full Text] [Related]
11. A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia.
Koller CA; Kantarjian HM; Feldman EJ; O'Brien S; Rios MB; Estey E; Keating M
Cancer; 1999 Dec; 86(11):2246-51. PubMed ID: 10590364
[TBL] [Abstract][Full Text] [Related]
12. Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes.
Anderlini P; Luna M; Kantarjian HM; O'Brien S; Pierce S; Keating MJ; Estey EH
Leukemia; 1996 Apr; 10(4):600-8. PubMed ID: 8618434
[TBL] [Abstract][Full Text] [Related]
13. FLAG-liposomal doxorubicin (Myocet) regimen for refractory or relapsed acute leukemia pediatric patients.
Quarello P; Berger M; Rivetti E; Galletto C; Masetti R; Manicone R; Barisone E; Pession A; Fagioli F
J Pediatr Hematol Oncol; 2012 Apr; 34(3):208-16. PubMed ID: 22395219
[TBL] [Abstract][Full Text] [Related]
14. Intensive consolidation chemotherapy versus standard consolidation maintenance in acute myelogenous leukemia (AML) in first remission. An EORTC/GIMEMA phase III trial (AML8 B). The EORTC Leukemia Cooperative Group and the GIMEMA Group.
Zittoun R; Liso V; Mandelli F; Rotoli B; de Witte T; Gattringer C; Resegotti L; Caronia F; Leoni P; Petti MC
Leukemia; 1992; 6 Suppl 2():76-7. PubMed ID: 1578949
[No Abstract] [Full Text] [Related]
15. Fludarabine and cytosine-arabinoside for poor-risk acute myeloid leukemia.
Russo D; Candoni A; Grattoni R; Bertone A; Zaja F
Haematologica; 1998 Mar; 83(3):281-2. PubMed ID: 9573683
[TBL] [Abstract][Full Text] [Related]
16. Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.
Clavio M; Venturino C; Pierri I; Garrone A; Miglino M; Canepa L; Balleari E; Balocco M; Michelis GL; Ballerini F; Gobbi M
Ann Hematol; 2004 Nov; 83(11):696-703. PubMed ID: 15322763
[TBL] [Abstract][Full Text] [Related]
17. Is allogeneic bone marrow transplantation the best treatment for young adult patients with acute myeloid leukemia in first complete remission. The BGMT Group.
Reiffers J; Stoppa AM; Rigal-Huguet F; Michallet M; Marit G; Blaise D; Attal M; Corront B; Cony-Makhoul P; Gastaut JA
Leukemia; 1992; 6 Suppl 2():124-6. PubMed ID: 1578913
[No Abstract] [Full Text] [Related]
18. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia.
Clavio M; Carrara P; Miglino M; Pierri I; Canepa L; Balleari E; Gatti AM; Cerri R; Celesti L; Vallebella E; Sessarego M; Patrone F; Ghio R; Damasio E; Gobbi M
Haematologica; 1996; 81(6):513-20. PubMed ID: 9009438
[TBL] [Abstract][Full Text] [Related]
19. Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia.
Tsimberidou AM; Estey E; Cortes JE; Garcia-Manero G; Faderl S; Verstovsek S; Thomas DA; Ferrajoli A; Keating MJ; O'Brien S; Kantarjian HM; Giles FJ
Cancer Chemother Pharmacol; 2003 Dec; 52(6):449-52. PubMed ID: 13680159
[TBL] [Abstract][Full Text] [Related]
20. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.
Yalman N; Sarper N; Devecioğlu O; Anak S; Eryilmaz E; Can M; Yenilmez H; Ağaoğlu L; Gedikoğlu G
Turk J Pediatr; 2000; 42(3):198-204. PubMed ID: 11105617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
